Search - tctmd.com

Displaying 1 - 20 of 36

Sort: Relevancy | Date

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

Newer Weight-Loss Drugs Not Cost-effective at Current Prices

News Daily News

Newer Weight-Loss Drugs Not Cost-effective at Current Prices

Michael O'Riordan

March 18, 2025

US Obesity Epidemic Continues to Skyrocket, With No End in Sight

News Conference News AHA 2024

US Obesity Epidemic Continues to Skyrocket, With No End in Sight

Michael O'Riordan

November 15, 2024

Many Patients Quit Taking GLP-1 Drugs: Understanding Why Is Key

News Daily News

Many Patients Quit Taking GLP-1 Drugs: Understanding Why Is Key

November 13, 2024

Statins Are Cost-effective in the Elderly

News Daily News

Statins Are Cost-effective in the Elderly

Michael O'Riordan

September 11, 2024

As Trends Reverse in CVD, AHA Warns of Soaring Costs and Illness

News Daily News

As Trends Reverse in CVD, AHA Warns of Soaring Costs and Illness

June 05, 2024

One in Three Overweight MI Patients May Benefit From Semaglutide

News Daily News

One in Three Overweight MI Patients May Benefit From Semaglutide

February 26, 2024

Prescribing a Generic for CVD? Plan, Drug Type, and Condition Impact Availability

News Daily News

Prescribing a Generic for CVD? Plan, Drug Type, and Condition Impact Availability

September 13, 2023

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

News Daily News

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Michael O'Riordan

July 20, 2023

Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF

News Daily News

Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF

March 15, 2023

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

News Daily News

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

Michael O'Riordan

November 29, 2022

FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses

News Conference News EAS 2022

FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses

Michael O'Riordan

May 26, 2022

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

Despite COVID-19 Heart Disease Remains Top US Killer AHA (1).jpeg

News Daily News

Despite COVID-19, Heart Disease Remains Top US Killer: AHA

Michael O'Riordan

January 28, 2021

Nearly Half of Diabetic Patients Struggle to Pay Medical Bills

News Daily News

Nearly Half of Diabetic Patients Struggle to Pay Medical Bills

Michael O'Riordan

February 12, 2020

ORION-11: Inclisiran Shows Promise, Safety in Largest Published Cohort

News Conference News ESC 2019

ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date

Yael L. Maxwell

September 03, 2019

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

CVD, Other Noncommunicable Diseases Hit Lower-Income Countries With Heavy Financial Burden

News Conference News WCC 2018

CVD, Other Noncommunicable Diseases Hit Lower-Income Countries With Heavy Financial Burden

December 06, 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

News Daily News

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

August 15, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.